Details of the Drug Combinations

General Information of This Drug (ID: DM72JXH)

• Drug Name: Losartan (DM72JXH)
• Synonyms: Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan

Indication

Diabetic kidney disease; ICD 11: GB61.Z; Status: Approved [1]; Hypertension; ICD 11: BA00-BA04; Status: Approved [2]; Prediabetes syndrome; ICD 11: N.A.; Status: Approved [1]; Coronavirus Disease 2019 (COVID-19); ICD 11: 1D6Y; Status: Phase 3 [3]

• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

20 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
3,7,3',4'-TETRAHYDROXYFLAVONE + Losartan	DCI7PS8	3,7,3',4'-TETRAHYDROXYFLAVONE	Osteoarthritis, Knee	[4]
Aliskiren + Losartan	DC62OED	Aliskiren	Diabetes Mellitus	[5]
Furosemide + Losartan	DCBQLEV	Furosemide	Essential Hypertension	[6]
Lisinopril + Losartan	DC2CU79	Lisinopril	Kidney Disease	[7]
Losartan + Hydrochlorothiazide	DCNS4JP	Hydrochlorothiazide	Hypertension; Hypertrophy, Left Ventricular	[8]
Resveratrol + Losartan	DCN39RC	Resveratrol	Diabetic Nephropathy	[9]
Spironolactone + Losartan	DCFC7WO	Spironolactone	Chronic Renal Disease	[10]
THIOCTIC ACID + Losartan	DCFDV8J	THIOCTIC ACID	Diabetic nephropathy	[11]
Valsartan + Losartan	DC0I0XI	Valsartan	Hypertension	[12]
Ivermectin + Losartan	DCSX87U	Ivermectin	Cancer	[13]
Losartan + Leucovorin	DC4IQ3M	Leucovorin	Pancreatic Cancer	[14]
Amlodipine + Losartan	DCWO32W	Amlodipine	Hypertension	[15]
Aspirin + Losartan	DC582R9	Aspirin	Covid-19	[3]
Prednisolone + Losartan	DC2LRUE	Prednisolone	COVID-19 Associated Cardiac Involvement	[16]
Simvastatin + Losartan	DCNU742	Simvastatin	Covid-19	[3]
Amlodipine + Losartan	DCIBFV5	Amlodipine	Hypertension	[17]
Empagliflozin + Losartan	DCATMLS	Empagliflozin	Diabetes Mellitus, Type 2	[18]
Losartan + Pentoxifylline	DCEBFDN	Pentoxifylline	Diabetic Nephropathies	[19]
Simvastatin + Losartan	DCOKJ0J	Simvastatin	Serious Mental Illness	[20]
Spironolactone + Losartan	DCJ9HE1	Spironolactone	End Stage Renal Disease	[21]

References

• [1] Losartan FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 590).
• [3] ClinicalTrials.gov (NCT04343001) Coronavirus Response - Active Support for Hospitalised Covid-19 Patients. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT04815902) Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
• [5] ClinicalTrials.gov (NCT00732407) Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)
• [6] ClinicalTrials.gov (NCT00151827) Olmesartan Medoxomil in Hypertension and Renal Impairment
• [7] ClinicalTrials.gov (NCT00555217) VA NEPHRON-D: Diabetes iN Nephropathy Study
• [8] ClinicalTrials.gov (NCT00446563) Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
• [9] ClinicalTrials.gov (NCT02704494) Resveratrol's Effects in Diabetic Nephropathy
• [10] ClinicalTrials.gov (NCT02190318) Residual Renal Function Preservation in Peritoneal Dialysis Patients
• [11] Therapeutic approaches to diabetic nephropathy--beyond the RAS. Nat Rev Nephrol. 2014 Jun;10(6):325-46.
• [12] ClinicalTrials.gov (NCT00732966) Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?
• [13] ClinicalTrials.gov (NCT04447235) Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection
• [14] ClinicalTrials.gov (NCT01821729) Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
• [15] ClinicalTrials.gov (NCT04074551) A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
• [16] ClinicalTrials.gov (NCT05619653) Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
• [17] ClinicalTrials.gov (NCT01176032) ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling
• [18] ClinicalTrials.gov (NCT04238702) Renohemodynamic Effects of Combined empagliflOzin and LosARtan
• [19] ClinicalTrials.gov (NCT03006952) Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy
• [20] ClinicalTrials.gov (NCT02188121) Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
• [21] ClinicalTrials.gov (NCT03953950) Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis Patients